Dr. Chapman Describes the Vemurafenib Clinical Trial

Video

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Paul Chapman, MD from the Memorial Sloan-Kettering Cancer Center describes the vemurafenib clinical trial.

Dr. Chapman says the vemurafenib trial was a phase III randomized trial for patients with melanoma who had never had prior therapy whose tumors had a mutation in the BRAF gene. These patients were randomized to either receive the experimental drug, vemurafenib, or a standard chemotherapy. Patients were randomized 1:1 and initially no crossover was allowed. The results were that the patients on the vemurafenib arm showed a decreased risk of death of 63%, and as a result the early analysis that showed that decrease led to allowing the patients on the standard chemotherapy drug to crossover to the experimental arm.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD